“It’s inconceivable!” This famous line and exchange from the 1987 classic film The Princess Bride, along with the fates of the characters Vizzini and Inigo Montoya, provide the fulcrum for this Journal of Clinical Oncology (JCO) editorial, which highlights the phase III TOURMALINE-MM1 trial and its seemingly “negative” findings in multiple myeloma (MM). Are we considering the inconceivable? Do we know what the word even means?

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy seen in children and adolescents and young adults (AYAs). This article highlights two recent studies that provide novel evidence of the association between obesity and increased risk of high-risk B-ALL and the effectiveness of a non-pharmacologic intervention for reducing minimal residual disease (MRD) risk.

In this article/podcast from KevinMD.com, Dr. Kristin Yates, an OB/GYN, describes her work as a doctor, which “brings me fulfillment and joy. It makes me a better doctor.” Dr. Yates also explains: “The fact of the matter is, I am not a doctor. I am a human being. Doctoring is what I do, not who I am. This distinction is very important to me because it is what has made medicine sustainable and fulfilling.”

The 27-member petition, which is led by Dr. Linda Wastila, a professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, calls the notion of approval to stimulate vaccination rates “backward logic.” The group of clinicians and researchers claim data should be from completed phase III trials, not interim results. “Slow down and get the science right,” the group wrote in a blog post published in The British Medical Journal.

We’ve all experienced a memory blip now and then, but these so-called “senior moments” could actually be signaling a bigger problem. Alzheimer’s disease (AD) is not a normal part of aging even though aging ups the risk for developing the condition. Here are 10 warning signs you can share with patients if they’re questioning what’s normal memory behavior and what’s not.  

The investigational new drug (IND) application is for GDX012, which also received an FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The drug’s manufacturer, GammaDelta Therapeutics, is developing the T-cell platform in partnership with Takeda and will initiate a phase I study in late 2021 that will evaluate the treatment’s safety and activity in patients with measurable residual disease-positive AML.